Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 18, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
August 13, 2025 16:30 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
August 05, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
July 23, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
July 03, 2025 16:30 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2025 06:55 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
June 23, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
June 02, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients
May 15, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial...
May 12, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited...